Skip to content
10-Q

Quarterly Report

ALX ONCOLOGY HOLDINGS INC ALXO

0000950170-25-066894

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 53.44M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $8.23M
Long Term Debt Q1 2025 · Dec 31, 2024 $9.47M
Short Term Debt Q1 2025 · Mar 31, 2025 $1.74M
Short Term Debt Q1 2025 · Dec 31, 2024 $435K
Short Term Investments Q1 2025 · Mar 31, 2025 $77.22M
Short Term Investments Q1 2025 · Dec 31, 2024 $110.19M
Current Liabilities Q1 2025 · Mar 31, 2025 $18.74M
Current Liabilities Q1 2025 · Dec 31, 2024 $18.5M
Total Liabilities Q1 2025 · Mar 31, 2025 $32.61M
Total Liabilities Q1 2025 · Dec 31, 2024 $34.16M
Current Assets Q1 2025 · Mar 31, 2025 $102.53M
Current Assets Q1 2025 · Dec 31, 2024 $134.35M
Total Assets Q1 2025 · Mar 31, 2025 $120.9M
Total Assets Q1 2025 · Dec 31, 2024 $147.78M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $17.57M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $14.04M
Shares Diluted Q1 2025 · Mar 31, 2024 50.12M sh
Capex Q1 2025 · Mar 31, 2024 $148K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$37.92M
Stockholders Equity Q1 2025 · Mar 31, 2024 $164.2M
Stockholders Equity Q1 2025 · Dec 31, 2023 $189.71M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.71
Eps Basic Q1 2025 · Mar 31, 2024 −$0.71
Sga Expense Q1 2025 · Mar 31, 2024 $6.05M
Rd Expense Q1 2025 · Mar 31, 2024 $31.72M
Net Income Q1 2025 · Mar 31, 2024 −$35.58M
Operating Income Q1 2025 · Mar 31, 2024 −$37.76M